Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T51408
|
||||
Former ID |
TTDC00184
|
||||
Target Name |
Beta-3 adrenergic receptor
|
||||
Gene Name |
ADRB3
|
||||
Synonyms |
Beta-3 adrenoceptor; Beta-3 adrenoreceptor; Beta3-AR; Beta3AR; ADRB3
|
||||
Target Type |
Successful
|
||||
Disease | Asthma [ICD10: J45] | ||||
Asthma; Chronic obstructive pulmonary disease [ICD9: 490-492, 493, 494-496; ICD10: J40-J44, J47, J45] | |||||
Angina pectoris [ICD9: 413; ICD10: I20] | |||||
Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1] | |||||
Glaucoma [ICD9: 365; ICD10: H40-H42] | |||||
Gastrointestinal disease [ICD10: K00-K93] | |||||
Hypertension [ICD9: 401; ICD10: I10-I16] | |||||
Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10: A09, K58, K59.1] | |||||
Major depressive disorder; Severe mood disorders [ICD9: 296, 296.2, 296.3; ICD10: F30-F39, F32, F33] | |||||
Major depressive disorder; Obesity; Type 2 diabetes [ICD9: 250, 250.00, 250.02, 278, 296, 296.2, 296.3; ICD10: E08-E13, E11, E66, F30-F39, F32, F33] | |||||
Neurogenic bladder dysfunction [ICD10: N31.9] | |||||
Overactive bladder disorder [ICD9: 188, 596.51; ICD10: C67, N32.81] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Obesity; Type 2 diabetes [ICD9: 250, 250.00, 250.02, 278; ICD10: E08-E13, E11, E66] | |||||
Type 2 diabetes [ICD9: 250; ICD10: E11] | |||||
Urinary incontinence [ICD9: 788.3; ICD10: N39.3, N39.4, R32] | |||||
Function |
Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
|
||||
BioChemical Class |
GPCR rhodopsin
|
||||
Target Validation |
T51408
|
||||
UniProt ID | |||||
Sequence |
MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLVIV
AIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSVDVLC VTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIMSQWWRV GADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVATRQLRLLRG ELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALCTLGLIMGT FTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDFRSAFRRLL CRCGRRLPPEPCAAARPALFPSGVPAARSSPAQPRLCQRLDGASWGVS |
||||
Structure |
2LSQ; 2CDW
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Amosulalol | Drug Info | Approved | Hypertension | [533886] |
Bitolterol | Drug Info | Approved | Asthma; Chronic obstructive pulmonary disease | [551871] | |
Bopindolol | Drug Info | Approved | Hypertension | [551871] | |
Mepindolol | Drug Info | Approved | Angina pectoris | [551871] | |
Mirabegron | Drug Info | Approved | Overactive bladder disorder | [532210], [542469] | |
Nipradilol | Drug Info | Approved | Angina pectoris | [551871] | |
Rimiterol | Drug Info | Approved | Asthma | [551871] | |
ASP-3652 | Drug Info | Phase 2 | Overactive bladder disorder | [523939] | |
AZ-40140 | Drug Info | Phase 2 | Obesity; Type 2 diabetes | [536122] | |
CL-316,243 | Drug Info | Phase 2 | Obesity | [533802], [540400] | |
CP-331684 | Drug Info | Phase 2 | Diabetes | [547126] | |
GW-427353 | Drug Info | Phase 2 | Urinary incontinence | [521908] | |
LY-362884 | Drug Info | Phase 2 | Obesity; Type 2 diabetes | [536122] | |
LY-377604 | Drug Info | Phase 2 | Obesity | [522816] | |
MK-4618 | Drug Info | Phase 2 | Overactive bladder disorder | [523395] | |
N-5984 | Drug Info | Phase 2 | Obesity; Type 2 diabetes | [536122] | |
YM-430 | Drug Info | Phase 2 | Hypertension | [534350] | |
ZD2079 | Drug Info | Phase 2 | Diabetes | [525938] | |
QLT-091568 | Drug Info | Phase 1/2 | Glaucoma | [522437] | |
BMS-196085 | Drug Info | Phase 1 | Diabetes | [526197] | |
EPI-12323 combination therapy | Drug Info | Phase 1 | Asthma; Chronic obstructive pulmonary disease | [547408] | |
KUC-7483 | Drug Info | Phase 1 | Overactive bladder disorder | [524942] | |
KUL-7211 | Drug Info | Phase 1 | Neurogenic bladder dysfunction | [547180] | |
Laevo-Bambuterol | Drug Info | Phase 1 | Asthma | [549077] | |
ZD7114 | Drug Info | Phase 1 | Diabetes | [525938] | |
Amibegron | Drug Info | Preclinical | Major depressive disorder; Obesity; Type 2 diabetes | [536580], [541023] | |
CL-314698 | Drug Info | Preclinical | Obesity; Type 2 diabetes | [536122] | |
CP-114271 | Drug Info | Preclinical | Obesity | [536122] | |
GCR-1087 | Drug Info | Preclinical | Obesity; Type 2 diabetes | [536122] | |
L-742791 | Drug Info | Preclinical | Obesity | [536122], [540405] | |
L-751250 | Drug Info | Preclinical | Obesity | [536122] | |
Bitolterol | Drug Info | Withdrawn from market | Asthma | [551871] | |
Epanolol | Drug Info | Discontinued in Preregistration | Angina pectoris | [544649] | |
PW-2101 | Drug Info | Discontinued in Preregistration | Angina pectoris | [547795] | |
Amibegron | Drug Info | Discontinued in Phase 3 | Major depressive disorder; Severe mood disorders | [536580], [541023] | |
Adaprolol maleate-SME | Drug Info | Discontinued in Phase 2 | Glaucoma | [545496] | |
ALPRENOXIME HYDROCHLORIDE | Drug Info | Discontinued in Phase 2 | Glaucoma | [545495] | |
OBERADILOL MONOETHYL MALEATE | Drug Info | Discontinued in Phase 2 | Hypertension | [545156] | |
PROXODOLOL | Drug Info | Discontinued in Phase 2 | Glaucoma | [546580] | |
Rafabegron | Drug Info | Discontinued in Phase 2 | Type 2 diabetes | [546607] | |
Tienoxolol | Drug Info | Discontinued in Phase 2 | Hypertension | [544571] | |
NCX 950 | Drug Info | Discontinued in Phase 1/2 | Asthma | [547021] | |
MN-246 | Drug Info | Discontinued in Phase 1 | Urinary incontinence | [548176] | |
PAFENOLOL | Drug Info | Discontinued in Phase 1 | Hypertension | [545184] | |
RO-16-8714 | Drug Info | Discontinued in Phase 1 | Diabetes | [544945] | |
SB 418790 | Drug Info | Discontinued in Phase 1 | Type 2 diabetes | [547143] | |
BMS-210285 | Drug Info | Terminated | Type 2 diabetes | [546852] | |
BRL 26830A | Drug Info | Terminated | Obesity | [544638] | |
BRL 37344 | Drug Info | Terminated | Discovery agent | [541013], [546206] | |
FR149175 | Drug Info | Terminated | Type 2 diabetes | [546562] | |
H-216/44 | Drug Info | Terminated | Glaucoma | [545911] | |
SM 11044 | Drug Info | Terminated | Asthma | [526162] | |
SR-58878 | Drug Info | Terminated | Irritable bowel syndrome | [549821] | |
SR-58894A | Drug Info | Terminated | Gastrointestinal disease | [546455] | |
Trecadrine | Drug Info | Terminated | Discovery agent | [545594] | |
Agonist | (-)-Ro 363 | Drug Info | [534368] | ||
Amibegron | Drug Info | [536580] | |||
ASP-3652 | Drug Info | [548857] | |||
AZ-40140 | Drug Info | [536122] | |||
BMS-210285 | Drug Info | [551898] | |||
BRL 26830A | Drug Info | [536256] | |||
BRL 37344 | Drug Info | [537970] | |||
Carazolol | Drug Info | [538095] | |||
CGP 12177 | Drug Info | [537970] | |||
CL-314698 | Drug Info | [536122] | |||
CL-316,243 | Drug Info | [535218] | |||
CP-114271 | Drug Info | [536122] | |||
CP-331684 | Drug Info | [551914] | |||
EPI-12323 combination therapy | Drug Info | [543746] | |||
FMP-825 | Drug Info | [543754] | |||
FR149175 | Drug Info | [538035] | |||
GCR-1087 | Drug Info | [536122] | |||
GW-427353 | Drug Info | [536122] | |||
KUC-7483 | Drug Info | [531824], [531877] | |||
L-742791 | Drug Info | [536122] | |||
L-751250 | Drug Info | [536122] | |||
LY-362884 | Drug Info | [536122] | |||
LY-377604 | Drug Info | [544405] | |||
MK-4618 | Drug Info | [549065] | |||
MN-246 | Drug Info | [550845] | |||
N-5984 | Drug Info | [536122] | |||
NCX 950 | Drug Info | [549952] | |||
prenalterol | Drug Info | [533129] | |||
SB 418790 | Drug Info | [551185] | |||
SB251023 | Drug Info | [526315] | |||
SM 11044 | Drug Info | [537970] | |||
SWR-0342SA | Drug Info | [537068] | |||
T-0509 | Drug Info | [534301] | |||
Trecadrine | Drug Info | [537984] | |||
Trimetoquinol | Drug Info | [534963] | |||
xamoterol | Drug Info | [525620] | |||
ZD2079 | Drug Info | [534855] | |||
ZD7114 | Drug Info | [534855] | |||
zinterol | Drug Info | [530999] | |||
[125I]ICYP | Drug Info | [526944] | |||
[3H](-)CGP 12177 | Drug Info | [527025] | |||
Inhibitor | 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol | Drug Info | [533374] | ||
1-(2-allylphenoxy)-3-morpholinopropan-2-ol | Drug Info | [530883] | |||
1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol | Drug Info | [530883] | |||
BMS-196085 | Drug Info | [528868] | |||
Modulator | Adaprolol maleate-SME | Drug Info | [534192] | ||
ALPRENOXIME HYDROCHLORIDE | Drug Info | [529137] | |||
Amosulalol | Drug Info | [533886], [551871] | |||
Bitolterol | Drug Info | [533490], [551871] | |||
Bopindolol | Drug Info | [532612], [551871] | |||
Epanolol | Drug Info | [530320] | |||
ER-23006 | Drug Info | [543746] | |||
H-216/44 | Drug Info | [533381] | |||
KUL-7211 | Drug Info | [526702] | |||
Laevo-Bambuterol | Drug Info | [543746] | |||
Mepindolol | Drug Info | [533373], [544004], [551871] | |||
Mirabegron | Drug Info | [532210] | |||
Nipradilol | Drug Info | [533522], [551871] | |||
OBERADILOL MONOETHYL MALEATE | Drug Info | [550931] | |||
PAFENOLOL | Drug Info | [533895] | |||
PROXODOLOL | Drug Info | [533804] | |||
Rafabegron | Drug Info | [528534] | |||
Rimiterol | Drug Info | [525848], [551871] | |||
RO-16-8714 | Drug Info | [533155] | |||
SR-58878 | Drug Info | [543754] | |||
SR-58894A | Drug Info | [527168] | |||
Tienoxolol | Drug Info | [533973] | |||
YM-430 | Drug Info | [534350] | |||
Binder | Beta-adrenoceptor ligands | Drug Info | [543746] | ||
Antagonist | cicloprolol | Drug Info | [525440] | ||
H87/07 | Drug Info | [525440] | |||
L-748337 | Drug Info | [525542] | |||
L748328 | Drug Info | [525542] | |||
LK 204-545 | Drug Info | [525440] | |||
NIHP | Drug Info | [525440] | |||
NIP | Drug Info | [525440] | |||
PW-2101 | Drug Info | [549748] | |||
QLT-091568 | Drug Info | [551556] | |||
[125I](-)ICYP | Drug Info | [527007] | |||
Blocker | MystiLol | Drug Info | [543746] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
Pathways | |||||
KEGG Pathway | Calcium signaling pathway | ||||
cGMP-PKG signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Endocytosis | |||||
Salivary secretion | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Beta3 adrenergic receptor signaling pathway | |||||
Reactome | Adrenoceptors | ||||
G alpha (s) signalling events | |||||
WikiPathways | Monoamine GPCRs | ||||
Calcium Regulation in the Cardiac Cell | |||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
Ref 521908 | ClinicalTrials.gov (NCT00394186) A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS). U.S. National Institutes of Health. | ||||
Ref 522437 | ClinicalTrials.gov (NCT00753168) Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma. U.S. National Institutes ofHealth. | ||||
Ref 522816 | ClinicalTrials.gov (NCT00993421) A Weight Loss Study in Overweight Men and Women. U.S. National Institutes of Health. | ||||
Ref 523395 | ClinicalTrials.gov (NCT01314872) A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM3 EXT1[AM2]). U.S. National Institutes of Health. | ||||
Ref 523939 | ClinicalTrials.gov (NCT01613586) A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC). U.S. National Institutes of Health. | ||||
Ref 524942 | ClinicalTrials.gov (NCT02256735) Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers. U.S.National Institutes of Health. | ||||
Ref 525938 | Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects. Int J Obes Relat Metab Disord. 2000 Dec;24(12):1553-60. | ||||
Ref 526162 | The iodocyanopindolol and SM-11044 binding protein belongs to the TM9SF multispanning membrane protein superfamily. Gene. 2001 Aug 8;273(2):227-37. | ||||
Ref 526197 | BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):3041-4. | ||||
Ref 533802 | Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance and brown and white adipose tissues in rats. Am J Physiol. 1994 Apr;266(4 Pt 2):R1371-82. | ||||
Ref 533886 | Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. | ||||
Ref 534350 | Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6. | ||||
Ref 536122 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
Ref 536580 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
Ref 540400 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3462). | ||||
Ref 540405 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3467). | ||||
Ref 541013 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 567). | ||||
Ref 541023 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 568). | ||||
Ref 542469 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7445). | ||||
Ref 544571 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000171) | ||||
Ref 544638 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000393) | ||||
Ref 544649 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000427) | ||||
Ref 544945 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001618) | ||||
Ref 545156 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002312) | ||||
Ref 545184 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002399) | ||||
Ref 545495 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003470) | ||||
Ref 545496 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003472) | ||||
Ref 545594 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003832) | ||||
Ref 545911 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005323) | ||||
Ref 546206 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006890) | ||||
Ref 546455 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008218) | ||||
Ref 546562 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008959) | ||||
Ref 546580 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009043) | ||||
Ref 546607 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009164) | ||||
Ref 546852 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010623) | ||||
Ref 547021 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012159) | ||||
Ref 547126 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013231) | ||||
Ref 547143 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013384) | ||||
Ref 547180 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013676) | ||||
Ref 547408 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015988) | ||||
Ref 547795 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019361) | ||||
Ref 548176 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022773) | ||||
Ref 525440 | LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5. | ||||
Ref 525542 | Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1999 Aug;290(2):649-55. | ||||
Ref 525620 | Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists. Mol Pharmacol. 1999 Nov;56(5):875-85. | ||||
Ref 525848 | Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8. | ||||
Ref 526315 | Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. Br J Pharmacol. 2002 Apr;135(8):1903-14. | ||||
Ref 526702 | Pharmacological profile of KUL-7211, a selective beta-adrenoceptor agonist, in isolated ureteral smooth muscle. J Pharmacol Sci. 2003 Aug;92(4):411-9. | ||||
Ref 526944 | Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. Eur J Pharmacol. 2004 Jan 26;484(2-3):323-31. | ||||
Ref 527007 | Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br J Pharmacol. 2004May;142(1):51-6. Epub 2004 Mar 22. | ||||
Ref 527025 | Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. | ||||
Ref 527168 | Pharmacological characterization of beta-adrenoceptor subtypes mediating relaxation in porcine isolated ureteral smooth muscle. J Urol. 2004 Sep;172(3):1155-9. | ||||
Ref 528534 | Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab. 2007 Feb;92(2):527-31. Epub 2006 Nov 21. | ||||
Ref 528868 | Bioorg Med Chem Lett. 2007 Aug 1;17(15):4290-6. Epub 2007 May 16.Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. | ||||
Ref 529137 | Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime--a new potential antiglaucoma agent. Pharm Res. 1991 Nov;8(11):1389-95. | ||||
Ref 530320 | Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris. Br J Clin Pharmacol. 1990 Mar;29(3):333-7. | ||||
Ref 530883 | Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. Epub 2010 Apr 9.A vHTS approach for the identification of beta-adrenoceptor ligands. | ||||
Ref 530999 | The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010 Jul;160(5):1048-61. | ||||
Ref 531824 | Mirabegron for the treatment of overactive bladder. Drugs Today (Barc). 2012 Jan;48(1):25-32. | ||||
Ref 531877 | Effects of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163-8. | ||||
Ref 532612 | Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. | ||||
Ref 533129 | Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar;35(3):295-303. | ||||
Ref 533155 | The novel thermogenic beta-adrenergic agonist Ro 16-8714 increases the interscapular brown-fat beta-receptor-adenylate cyclase and the uncoupling-protein mRNA level in obese (fa/fa) Zucker rats. Biochem J. 1989 Aug 1;261(3):721-4. | ||||
Ref 533373 | Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3. | ||||
Ref 533374 | J Med Chem. 1986 Aug;29(8):1524-7.Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols. | ||||
Ref 533381 | Binding of the beta-blockers timolol and H 216/44 to ocular melanin. Exp Eye Res. 1988 Oct;47(4):565-77. | ||||
Ref 533490 | Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37. | ||||
Ref 533522 | Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69. | ||||
Ref 533804 | The efficacy of proxodolol, a new beta-adrenoblockader with alpha-adrenoblockader properties, in its single use in patients with stable stenocardia of effort. Eksp Klin Farmakol. 1994 May-Jun;57(3):47-50. | ||||
Ref 533886 | Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. | ||||
Ref 533895 | Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans. Drug Metab Dispos. 1993May-Jun;21(3):435-40. | ||||
Ref 533973 | Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human parotid and submandibular-sublingual salivary secretion. J Dent Res. 1994 Jan;73(1):5-10. | ||||
Ref 534192 | Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. J Ocul Pharmacol Ther. 1996 Summer;12(2):115-22. | ||||
Ref 534301 | Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Eur J Pharmacol. 1996 Nov 21;315(3):363-7. | ||||
Ref 534350 | Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6. | ||||
Ref 534368 | Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Br J Pharmacol. 1997 Jan;120(2):165-76. | ||||
Ref 534855 | Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70. | ||||
Ref 534963 | Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro. J Med Chem. 2000 Feb 24;43(4):591-8. | ||||
Ref 535218 | Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49. | ||||
Ref 536122 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
Ref 536256 | Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice. Endocrinol Jpn. 1991 Aug;38(4):397-403. | ||||
Ref 536580 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
Ref 537970 | Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34. | ||||
Ref 537984 | Potential anti-diabetic applications of a new molecule with affinity for beta 3-adrenoceptors. Life Sci. 1996;59(11):PL141-6. | ||||
Ref 538035 | FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12. | ||||
Ref 538095 | Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. | ||||
Ref 543746 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29). | ||||
Ref 543754 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 30). | ||||
Ref 544004 | Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.. Br J Clin Pharmacol. 1982; 13(Suppl 2): 187S-192S. | ||||
Ref 544405 | Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity. ACS Med Chem Lett. 2011 August 11; 2(8): 583-586. | ||||
Ref 548857 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029610) | ||||
Ref 549065 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031896) | ||||
Ref 549748 | PW 2101 Penwest discontinued, USA (hypertension) Penwest non-approvable, USA (hypertension), R & D Focus Drug News. July 11, 2005 | ||||
Ref 549952 | A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities. JPET July 2004 vol. 310 no. 1 367-375. | ||||
Ref 550845 | CA patent application no. 630818, Pharmaceutical composition for prevention or treatment of neurogenic pain. | ||||
Ref 550931 | US patent application no. 9,062,094, Dipeptide-based prodrug linkers for aliphatic amine-containing drugs. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.